| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| paclitaxel | Injection, concentrated | 6 mg/mL | Resolved | Available | Manufacturing | 7/02/2025 |
| colistimethate sodium | Injection, powder for | IU | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 7/02/2025 |
| olanzapine | Tablet, orally disintegrating | 20 mg | Anticipated | Available | Manufacturing | 7/02/2025 |
| levetiracetam | Tablet, film coated | 250 mg | Current | Unavailable | Manufacturing | 7/02/2025 |
| capecitabine | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in consumer demand | 7/02/2025 |
| nicorandil | Tablet | 10 mg | Anticipated | Available | Manufacturing | 7/02/2025 |
| ivabradine hydrochloride | Tablet, film coated | 5.39 mg | Resolved | Available | Manufacturing | 7/02/2025 |
| fentanyl citrate | Injection, solution | 157 microgram | Resolved | Available | Manufacturing | 7/02/2025 |
| fluorouracil | Cream | 50 mg/g | Current | Unavailable | Manufacturing | 7/02/2025 |
| clindamycin phosphate | Lotion | 10 mg/mL | Resolved | Available | Manufacturing | 7/02/2025 |
| ropivacaine hydrochloride~fentanyl citrate | Injection, solution | 2 mg/mL~6.28 microgram/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 7/02/2025 |
| ropivacaine hydrochloride~fentanyl citrate | Injection, solution | 2 mg/mL~6.28 microgram/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 7/02/2025 |
| citalopram hydrobromide | Tablet, film coated | 49.96 mg | Anticipated | Available | Manufacturing | 7/02/2025 |
| carvedilol | Tablet, film coated | 6.25 mg | Resolved | Available | Manufacturing | 6/02/2025 |
| ramipril | Capsule, hard | 1.25 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
| octreotide | Injection, solution | 100 microgram | Current | Limited Availability | Manufacturing | 6/02/2025 |
| octreotide | Injection, solution | 500 microgram | Current | Unavailable | Manufacturing | 6/02/2025 |
| octreotide | Injection, solution | 50 microgram | Current | Limited Availability | Manufacturing | 6/02/2025 |
| topiramate | Tablet, film coated | 200 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
| olanzapine | Tablet, film coated | 10 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
| amisulpride | Tablet | 100 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
| trandolapril | Capsule, hard | .5 mg | Resolved | Available | Manufacturing | 6/02/2025 |
| trandolapril | Capsule, hard | 1 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
| trandolapril | Capsule, hard | 4 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
| risperidone | Tablet, film coated | 2 mg | Current | Unavailable | Unexpected increase in consumer demand | 6/02/2025 |
| quetiapine fumarate | Tablet, modified release | 345.39 mg | Anticipated | Available | Unexpected increase in consumer demand | 6/02/2025 |
| quetiapine fumarate | Tablet, modified release | 57.565 mg | Anticipated | Available | Unexpected increase in consumer demand | 6/02/2025 |
| candesartan cilexetil | Tablet, uncoated | 4 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
| esomeprazole | Capsule, enteric | 40 mg | Current | Unavailable | Manufacturing | 6/02/2025 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
| dosulepin (dothiepin) hydrochloride | Tablet, film coated | 75 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 6/02/2025 |
| doxepin hydrochloride | Capsule, hard | 11.3 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Current | Limited Availability | Unexpected increase in consumer demand | 6/02/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.376 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Unavailable | Unexpected increase in consumer demand | 6/02/2025 |
| levothyroxine sodium | Tablet, uncoated | 50 microgram | Current | Unavailable | Manufacturing | 6/02/2025 |
| metformin hydrochloride | Tablet, film coated | 850 mg | Current | Limited Availability | Manufacturing | 6/02/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 2.32 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 6/02/2025 |
| alprostadil | Injection, powder for | 40 microgram/mL | Current | Unavailable | Manufacturing | 6/02/2025 |
| nizatidine | Capsule | 150 mg | Anticipated | Available | Manufacturing | 6/02/2025 |
| betiatide | Injection, powder for | 1 mg | Current | Unavailable | Manufacturing | 5/02/2025 |
| acetylcholine chloride | Solution, powder for irrigation | 10 mg/mL | Current | Limited Availability | Manufacturing | 5/02/2025 |
| sumatriptan succinate | Tablet, film coated | 140 mg | Current | Unavailable | Manufacturing | 5/02/2025 |
| sugammadex sodium | Injection, solution | 217.6 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 5/02/2025 |
| acetylcysteine | Injection, concentrated | 2 g | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 5/02/2025 |
| nicotinic acid | Tablet, uncoated | 250 mg | Resolved | Available | Manufacturing | 5/02/2025 |
| fluorouracil | Injection, solution | 50 mg/mL | Current | Unavailable | Manufacturing | 5/02/2025 |
| deferasirox | Tablet, film coated | 90 mg | Anticipated | Available | Manufacturing | 5/02/2025 |
| melatonin | Oral Liquid, solution | 1 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 5/02/2025 |
| carbidopa monohydrate~levodopa | Tablet, uncoated | 26.9 mg~100 mg | Current | Limited Availability | Manufacturing | 5/02/2025 |
| imipramine hydrochloride | Tablet, sugar coated | 25 mg | Current | Unavailable | Manufacturing | 5/02/2025 |
| norethisterone~ethinylestradiol | Tablet, uncoated | 1 mg~36 microgram | Current | Limited Availability | Manufacturing | 5/02/2025 |
| citalopram hydrobromide | Tablet, film coated | 24.98 mg | Current | Limited Availability | Manufacturing | 5/02/2025 |
| nizatidine | Capsule | 300 mg | Resolved | Available | Manufacturing | 5/02/2025 |
| sodium pertechnetate(99mTc) | Injection, solution | 18.5 GBq | Current | Unavailable | Manufacturing | 4/02/2025 |
| clonidine hydrochloride | Tablet, uncoated | 100 microgram | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 4/02/2025 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 4/02/2025 |
| adrenaline (epinephrine) acid tartrate | Injection, solution | 182 microgram/mL | Current | Unavailable | Manufacturing | 4/02/2025 |
| mesalazine | Tablet, enteric coated | 800 mg | Current | Limited Availability | Manufacturing | 4/02/2025 |
| emtricitabine~tenofovir disoproxil fumarate | Tablet, film coated | 200 mg~300 mg | Current | Limited Availability | Manufacturing | 4/02/2025 |
| Influenza virus haemagglutinin | Injection, suspension | 15 microgram | Current | Unavailable | Seasonal depletion of stock | 4/02/2025 |
| mefenamic acid | Capsule, hard | 250 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 4/02/2025 |
| nebivolol hydrochloride | Tablet | 5.45 mg | Resolved | Available | Manufacturing | 4/02/2025 |
| Influenza virus haemagglutinin | Injection, suspension | 15 microgram | Current | Unavailable | Seasonal depletion of stock | 4/02/2025 |
| albendazole | Tablet, chewable | 200 mg | Resolved | Available | Manufacturing | 4/02/2025 |
| cisatracurium besilate | Injection, solution | 2.68 mg/mL | Current | Unavailable | Manufacturing | 4/02/2025 |
| estradiol~norethisterone acetate | Drug delivery system, transdermal | .62 mg~2.7 mg | Current | Unavailable | Manufacturing | 4/02/2025 |
| hydrocortisone acetate | Eye Ointment | 10 mg/g | Resolved | Available | Manufacturing | 3/02/2025 |
| fentanyl | Drug delivery system, transdermal | 4.2 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 3/02/2025 |
| tramadol hydrochloride | Tablet, modified release | 200 mg | Resolved | Available | Manufacturing | 3/02/2025 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 3/02/2025 |
| silver sulfadiazine | Cream | 10 mg/g | Current | Unavailable | Manufacturing | 3/02/2025 |
| heparin sodium | Injection, solution | 25000 IU/mL | Resolved | Available | Manufacturing | 3/02/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~41.583 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| rosuvastatin calcium~ezetimibe | Tablet~Tablet, film coated | 10.396 mg~10 mg | Current | Limited Availability | Manufacturing | 3/02/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~20.791 mg | Current | Limited Availability | Manufacturing | 3/02/2025 |
| ezetimibe~rosuvastatin calcium | Tablet~Tablet, film coated | 10 mg~5.198 mg | Current | Limited Availability | Manufacturing | 3/02/2025 |
| midazolam | Injection, solution | 5 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 3/02/2025 |
| eftrenonacog alfa | Injection, powder for | 250 IU | Resolved | Available | Unexpected increase in consumer demand | 3/02/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 43.4 mg~10 mg | Resolved | Available | Manufacturing | 3/02/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, multilayer | 86.8 mg~10 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 3/02/2025 |
| olmesartan medoxomil~amlodipine besilate | Tablet, film coated | 40 mg~6.935 mg | Resolved | Available | Manufacturing | 3/02/2025 |
| nebivolol hydrochloride | Tablet | 1.363 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| clobazam | Tablet, uncoated | 10 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| dasatinib propylene glycol | Tablet, film coated | 58 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| dasatinib propylene glycol | Tablet, film coated | 81.2 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| dasatinib propylene glycol | Tablet, film coated | 116 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| nitrofurantoin | Capsule, hard | 100 mg | Anticipated | Available | Manufacturing | 3/02/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Unavailable | Manufacturing | 3/02/2025 |
| carboplatin | Injection, solution | 10 mg/mL | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 3/02/2025 |
2025年2月10日